Skip to main content
Free access
Research Article
29 March 2019

Treatment of gynecological malignancies: long-term follow-up of health-related quality of life and healthcare costs

Abstract

Aim: To assess long-term health-related quality of life (HRQoL) and treatment-related costs in gynecological cancer patients, and to compare HRQoL between cancer types and to age-standardized general female population. Materials & methods: A prospective 8–10-year follow-up of 218 patients treated in Helsinki University Hospital in 2002–2004. Results: The most common malignancies were uterine, ovarian and cervical cancers. The mean HRQoL scores were 0.880 (baseline), 0.885 (6 months) and 0.884 for survivors in the end of the study. Depression, vitality and sexual activity were impaired at baseline but improved during follow-up. Total secondary healthcare costs during the follow-up averaged EUR 41342. Conclusion: The long-term HRQoL of surviving gynecological cancer patients was good and similar to that of age-standardized general female population.

Supplementary Material

File (suppl_file.docx)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
The WHO International Agency for Research on Cancer (2018). www.iarc.fr/index.php.
3.
Centers for Disease Control and Prevention (2018). www.cdc.gov/cancer/gynecologic/index.htm.
5.
Syöpäjärjestöt Finnish Cancer Association (2018). www.cancer.fi/.
6.
Finnish Cancer Register, Cancer Statistics of the National Institute of Health and Welfare (2018). www.cancer.fi/syoparekisteri/en/.
7.
Whiteman MK, Hillis SD, Jamieson DJ et al. Inpatient hysterectomy surveillance in the United States, 2000–2004. Am. J. Obstet. Gynecol. 198, 34.e1–34.e7 (2008).
8.
Ferrandina G, Petrillo M, Mantegna G et al. Evaluation of quality of life and emotional distress in endometrial cancer patients: a 2-year prospective, longitudinal study. Gynecol. Oncol. 133(3), 518–525 (2014).
• A 2-year follow-up of quality of life aspects of patients with endometrial cancer.
9.
Greimel E, Kristensen GB, van der Burg ME et al. Quality of life of advanced ovarian cancer patients in the randomized Phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecol. Oncol. 131(2), 437–444 (2013).
10.
Carter J, Sonoda Y, Baser RE et al. A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. Gynecol. Oncol. 119(2), 358–365 (2010).
• A 2-year follow-up of the quality of life of cervical cancer patients.
11.
Le T, Menard C, Samant R et al. Longitudinal assessments of quality of life in endometrial cancer patients: effect of surgical approach and adjuvant radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 75(3), 795–802 (2009).
12.
Dahl L, Wittrup I, Væggemose U, Petersen LK, Blaakaer J. Life after gynecologic cancer – a review of patients quality of life, needs, and preferences in regard to follow-up. Int. J. Gynecol. Cancer 23(2), 227–234 (2013).
•• A systematic review on the quality of life and the needs and preferences during follow-up of gynecological cancer survivors.
13.
Lutgendorf SK, Shinn E, Carter J et al. Quality of life among long-term survivors of advanced stage ovarian cancer: a cross-sectional approach. Gynecol. Oncol. 146(1), 101–108 (2017).
• Quality of life of ovarian cancer patients eight years after treatment initiation.
14.
Minig L, Vélez JI, Trimble EL, Biffi R, Maggioni A, Jeffery DD. Changes in short-term health-related quality of life in women undergoing gynecologic oncologic laparotomy: an associated factor analysis. Support. Care Cancer 21(3), 715–726 (2013).
15.
Bjelic-Radisic V, Jensen PT, Vlasic KK et al. Quality of life characteristics in patients with cervical cancer. Eur. J. Cancer 48(16), 3009–3018 (2012).
• A 2-year follow-up of quality of life of patients with cervical cancer.
16.
Westin SN, Sun CC, Tung CS et al. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J. Cancer Surviv. 10(2), 261–270 (2016).
•• A systematic stratified sample of the health concerns of gynecological cancer survivors.
17.
Hawighorst-Knapstein S, Fusshoeller C, Franz C et al. The impact of treatment for genital cancer on quality of life and body image – results of a prospective longitudinal 10-year study. Gynecol. Oncol. 94(2), 398–403 (2004).
18.
Grimm D, Hasenburg A, Eulenburg C et al. Sexual activity and function in patients with gynecological malignancies after completed treatment. Int. J. Gynecol. Cancer 25(6), 1134–1141 (2015).
19.
Yavas G, Dogan NU, Yavas C, Benzer N, Yuce D, Celik C. Prospective assessment of quality of life and psychological distress in patients with gynecologic malignancy: a 1-year prospective study. Int. J. Gynecol. Cancer 22(6), 1096–1101 (2012).
20.
Ditto A, Martinelli F, Borreani C et al. Quality of life and sexual, bladder, and intestinal dysfunctions after class III nerve-sparing and class II radical hysterectomies: a questionnaire-based study. Int. J. Gynecol. Cancer 19(5), 953–957 (2009).
21.
Bijen CB, Vermeulen KM, Mourits MJ et al. Cost–effectiveness of laparoscopy versus laparotomy in early stage endometrial cancer: a randomised trial. Gynecol. Oncol. 121(1), 76–82 (2011).
22.
Spirtos NM, Schlaerth JB, Gross GM, Spirtos TW, Schlaerth AC, Ballon SC. Cost and quality-of-life analyses of surgery for early endometrial cancer: laparotomy versus laparoscopy. Am. J. Obstet. Gynecol. 174(6), 1795–1799; discussion 1799-1800 (1996).
23.
Ashih H, Gustilo-Ashby T, Myers ER et al. Cost–effectiveness of treatment of early stage endometrial cancer. Gynecol. Oncol. 74(2), 208–216 (1999).
24.
Ferrandina G, Marcellusi A, Mennini FS, Petrillo M, Di Falco C, Scambia G. Hospital costs incurred by the Italian National Health Service for invasive cervical cancer. Gynecol. Oncol. 119(2), 243–249 (2010).
25.
Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long KH. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis. Gynecol. Oncol. 112(1), 16–21 (2009).
26.
Pynnä K, Vuorela P, Lodenius L, Paavonen J, Roine RP, Räsänen P. Cost–effectiveness of hysterectomy for benign gynecological conditions: a systematic review. Acta Obstet. Gynecol. Scand. 93(3), 225–232 (2014).
27.
Taipale K, Leminen A, Räsänen P et al. Cost and health-related quality of life effects of hysterectomy in patients with benign uterine disorders. Acta Obstet. Gynecol. Scand. 88(12), 1402–1410 (2009).
28.
Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann. Med. 33(5), 328–336 (2001).
29.
The 15D health-related quality of life (HRQoL) instrument (2018). www.15d-instrument.net/15D.
30.
Alanne S, Roine RP, Räsänen P, Vainiola T, Sintonen H. Estimating the minimum important change in the 15D scores. Qual. Life Res. 24(3), 599–606 (2015).
31.
Färkkilä N, Sintonen H, Saarto T et al. Health-related quality of life in colorectal cancer. Colorectal Dis. 15, e215–e222 (2013).
32.
Torvinen S, Färkkilä N, Sintonen H, Saarto T, Roine RP, Taari K. Health-related quality of life in prostate cancer. Acta Oncol. 52, 1094–1010 (2013).
33.
Loimu V, Mäkitie AA, Bäck LJ et al. Health-related quality of life of head and neck cancer patients with successful oncological treatment. Eur. Arch. Otorhinolaryngol. 272, 2415–2423 (2015).
34.
Richardson J, Iezzi A, Khan MA, Chen G, Maxwell A. Measuring the sensitivity and construct validity of 6 utility instruments in 7 disease areas. Med. Decis. Making 36(2), 147–159 (2016).
35.
Aromaa A, Koskinen S. Health and functional capacity in Finland. Baseline results of the Health 2000 Health Examination Survey. Helsinki, Finland (2004). www.julkari.fi/handle/10024/78534.
36.
Koskinen S, Lundqvist A, Ristoluoma N. Health, functional capacity and welfare in Finland in 2011. National Institute for Health and Welfare (THL), Report 68/2012. Helsinki, Finland (2012). www.julkari.fi/bitstream/handle/10024/90832/Rap068_2012_netti.pdf.
37.
Heistaro S. Methodology Report. Health 2000 Survey. Publications of the National Public Health Institute. Helsinki, Finland (2008). www.julkari.fi/handle/10024/78185.
38.
Lundqvist A, Mäki-Opas T. Health 2011 Survey – Methods. National Institute for Health and Welfare. Tampere, Finland (2016).
39.
The Association of the Nordic Cancer Registries (ANCR) (2018). www-dep.iarc.fr/NORDCAN/english/frame.asp.
40.
Herce Lopez J, Rollon Mayordomo A, Lozano Rosado R, Salazar Fernandez CI, Gallana S. Quality of life in long-term oral cancer survivors: a comparison with Spanish general population norms. J. Oral Maxillofac. Surg. 67(8), 1607 Tampere 1614 (2009).
41.
Feeny D, Krahn M, Prosser LA, Salomon JA. Valuing health outcomes. In: Cost–Effectiveness in Health and Medicine, Second Edition Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (Eds). Oxford University Press, NY, USA 167–199 (2016).
42.
Stafford L, Judd F. Long-term quality of life in Australian women previously diagnosed with gynaecologic cancer. Support. Care Cancer 19 (12), 2047 (2011).
•• A 5-year follow-up of the quality of life of gynecological cancer patients.
43.
Carter J, Stabile C, Gunn A, Sonoda Y. The physical consequences of gynecologic cancer surgery and their impact on sexual, emotional, and quality of life issues. J. Sex Med. 10(Suppl. 1), 21–34 (2013).
44.
Gordon LG, Scuffham PA, Beesley VL et al. Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 years. Int. J. Gynecol. Cancer 20(5), 757–765 (2010).
• A 2.5-year follow-up of medical costs and quality-adjusted life-years (survival adjusted by quality-of-life) of ovarian cancer patients.
45.
Forde GK, Chang J, Ziogas A, Tewari K, Bristow RE. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population. Gynecol. Oncol. 137(3), 479–484 (2015).
46.
Zakhari A, Czuzoj-Shulman N, Spence AR, Gotlieb WH, Abenhaim HA. Laparoscopic and robot-assisted hysterectomy for uterine cancer: a comparison of costs and complications. Am. J. Obstet. Gynecol. 213(5), 665.e1ee7 (2015).